{"success":true,"data":{"pressRelease":{"id":"99448","rtpr_id":"nGNX3PlZw9","ticker":"CAPR","exchange":"NASDAQ","all_tickers":["CAPR"],"title":"Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel","author":"Globe Newswire","published_at":"2026-07-27T17:58:08.095Z","article_body":"SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is\ninvestigating whether Capricor Therapeutics, Inc. (“Capricor” or the\n“Company”) (NASDAQ: CAPR) or certain of its officers and directors\nviolated federal securities laws by misrepresenting or failing to timely\ndisclose material information to investors.\n\nWhat if I purchased Capricor securities?\nIf you purchased Capricor securities and suffered losses on your investment,\nyou may join our investigation now: Click Here to Join the Investigation\n(https://www.globenewswire.com/Tracker?data=X-37xALf8hVp7dKraAPcjmjbmpPmCzrwPaMlu2Au3UFKzbuUN4BY6wHpq41ZqZS-Hq0mgLRtZtCYYVhpryovcETBT22aiHXWhMEJbfXecJxVsvXX2p520U3HxMyihA3mZd8oRp33zMVQw4v-jWkjY91D0QzsA_lMORt8MkJm7B7ESvo-UR9tCLdMwNCsVjW1).\n\nOr for more information, contact James Baker at jimb@johnsonfistel.com or\n(619) 814-4471.\n\nThere is no cost or obligation to you.\n\nWhat is Johnson Fistel Investigating?\nOn July 27, 2026, Reuters reported that U.S. Food and Drug Administration\nstaff reviewers raised concerns regarding the effectiveness data supporting\nderamiocel, Capricor’s experimental cell therapy for a heart condition\nassociated with Duchenne muscular dystrophy. According to Reuters, the FDA\nbriefing documents were released ahead of a meeting at which the agency’s\nexternal advisers are scheduled to discuss deramiocel’s effectiveness and\nrisk-benefit profile.\n\nReuters reported that FDA staff stated that Capricor changed how it measured\nthe principal results after the therapy’s late-stage trial ended. According\nto the report, Capricor calculated arm-function performance as a percentage\nchange rather than analyzing scores using the originally planned 42-point\ntest.\n\nAccording to Reuters, FDA staff did not consider the conversion from raw\nchange to percentage change and then back to raw change scientifically\njustified, stating that the approach added complexity and reduced accuracy.\n\nReuters further reported that FDA reviewers questioned whether the trial\npopulation had cardiomyopathy related to Duchenne muscular dystrophy because\npatients had normal heart-pumping function on average at the beginning of the\ntrial.\n\nFollowing this news, Capricor’s stock price declined approximately 70% in\nearly trading on July 27, 2026, resulting in significant losses for investors.\n\nInvestors who purchased Capricor securities and suffered losses are encouraged\nto contact Johnson Fistel to discuss their rights and potential recovery\noptions. There is no cost or obligation to participate.\n\nAbout Johnson Fistel, PLLP\nJohnson Fistel, PLLP is a nationally recognized shareholder rights law firm\nwith offices in California, New York, Georgia, Idaho, and Colorado. The firm\nrepresents individual and institutional investors in shareholder derivative\nand securities class action lawsuits. For more information about the firm and\nits attorneys, please visit www.johnsonfistel.com.\n\nAttorney advertising.\nPast results do not guarantee future outcomes.\nServices may be performed by attorneys in any of our offices.\n\nJohnson Fistel, PLLP has paid for the dissemination of this promotional\ncommunication, and Frank J. Johnson is the attorney responsible for its\ncontent.\n\nContact:\nJohnson Fistel, PLLP\n501 W. Broadway, Suite 800, San Diego, CA 92101\nJames Baker, Investor Relations or Frank J. Johnson, Esq., (619) 814-4471\njimb@johnsonfistel.com or fjohnson@johnsonfistel.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX3PlZw9","title":"Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel","author":"Globe Newswire","ticker":"CAPR","created":"2026-07-27T17:58:08.095Z","tickers":["CAPR"],"exchange":"NASDAQ","article_body":"SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is\ninvestigating whether Capricor Therapeutics, Inc. (“Capricor” or the\n“Company”) (NASDAQ: CAPR) or certain of its officers and directors\nviolated federal securities laws by misrepresenting or failing to timely\ndisclose material information to investors.\n\nWhat if I purchased Capricor securities?\nIf you purchased Capricor securities and suffered losses on your investment,\nyou may join our investigation now: Click Here to Join the Investigation\n(https://www.globenewswire.com/Tracker?data=X-37xALf8hVp7dKraAPcjmjbmpPmCzrwPaMlu2Au3UFKzbuUN4BY6wHpq41ZqZS-Hq0mgLRtZtCYYVhpryovcETBT22aiHXWhMEJbfXecJxVsvXX2p520U3HxMyihA3mZd8oRp33zMVQw4v-jWkjY91D0QzsA_lMORt8MkJm7B7ESvo-UR9tCLdMwNCsVjW1).\n\nOr for more information, contact James Baker at jimb@johnsonfistel.com or\n(619) 814-4471.\n\nThere is no cost or obligation to you.\n\nWhat is Johnson Fistel Investigating?\nOn July 27, 2026, Reuters reported that U.S. Food and Drug Administration\nstaff reviewers raised concerns regarding the effectiveness data supporting\nderamiocel, Capricor’s experimental cell therapy for a heart condition\nassociated with Duchenne muscular dystrophy. According to Reuters, the FDA\nbriefing documents were released ahead of a meeting at which the agency’s\nexternal advisers are scheduled to discuss deramiocel’s effectiveness and\nrisk-benefit profile.\n\nReuters reported that FDA staff stated that Capricor changed how it measured\nthe principal results after the therapy’s late-stage trial ended. According\nto the report, Capricor calculated arm-function performance as a percentage\nchange rather than analyzing scores using the originally planned 42-point\ntest.\n\nAccording to Reuters, FDA staff did not consider the conversion from raw\nchange to percentage change and then back to raw change scientifically\njustified, stating that the approach added complexity and reduced accuracy.\n\nReuters further reported that FDA reviewers questioned whether the trial\npopulation had cardiomyopathy related to Duchenne muscular dystrophy because\npatients had normal heart-pumping function on average at the beginning of the\ntrial.\n\nFollowing this news, Capricor’s stock price declined approximately 70% in\nearly trading on July 27, 2026, resulting in significant losses for investors.\n\nInvestors who purchased Capricor securities and suffered losses are encouraged\nto contact Johnson Fistel to discuss their rights and potential recovery\noptions. There is no cost or obligation to participate.\n\nAbout Johnson Fistel, PLLP\nJohnson Fistel, PLLP is a nationally recognized shareholder rights law firm\nwith offices in California, New York, Georgia, Idaho, and Colorado. The firm\nrepresents individual and institutional investors in shareholder derivative\nand securities class action lawsuits. For more information about the firm and\nits attorneys, please visit www.johnsonfistel.com.\n\nAttorney advertising.\nPast results do not guarantee future outcomes.\nServices may be performed by attorneys in any of our offices.\n\nJohnson Fistel, PLLP has paid for the dissemination of this promotional\ncommunication, and Frank J. Johnson is the attorney responsible for its\ncontent.\n\nContact:\nJohnson Fistel, PLLP\n501 W. Broadway, Suite 800, San Diego, CA 92101\nJames Baker, Investor Relations or Frank J. Johnson, Esq., (619) 814-4471\njimb@johnsonfistel.com or fjohnson@johnsonfistel.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-07-27T17:58:08.144098137Z","server_sent_at_ms":1785175088144},"received_at":"2026-07-27T17:58:08.196Z","source_url":null},"analysis":{"id":"88486","press_release_id":"99448","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Johnson Fistel, PLLP is investigating Capricor Therapeutics regarding potential federal securities violations tied to the disclosure of information about its experimental cell therapy deramiocel.\n\nThe investigation follows a Reuters report detailing FDA staff concerns over the effectiveness data and the analytical methodology used in the therapy's late-stage trial.\n\nCapricor's stock price reportedly declined approximately 70% on July 27, 2026, after the FDA briefing documents were released, prompting the law firm to solicit affected investors.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"James Baker","role":"Investor Relations"},{"name":"Frank J. Johnson","role":"Attorney"}],"products":["deramiocel"],"companies":[{"name":"Johnson Fistel, PLLP","relationship":"plaintiff law firm"},{"name":"Capricor Therapeutics, Inc.","ticker":"CAPR","relationship":"target"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"},{"name":"Reuters","relationship":"news source"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Johnson Fistel. No new disclosure from the issuer; no certified class, no settlement. Boilerplate investigation notice following reported FDA concerns."},"tickerRelevance":{"others":[],"primary":"CAPR"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Johnson Fistel, PLLP is investigating Capricor Therapeutics regarding potential federal securities violations tied to the disclosure of information about its experimental cell therapy deramiocel.\n\nThe investigation follows a Reuters report detailing FDA staff concerns over the effectiveness data and the analytical methodology used in the therapy's late-stage trial.\n\nCapricor's stock price reportedly declined approximately 70% on July 27, 2026, after the FDA briefing documents were released, prompting the law firm to solicit affected investors.","key_figures":{},"named_entities":{"people":[{"name":"James Baker","role":"Investor Relations"},{"name":"Frank J. Johnson","role":"Attorney"}],"products":["deramiocel"],"companies":[{"name":"Johnson Fistel, PLLP","relationship":"plaintiff law firm"},{"name":"Capricor Therapeutics, Inc.","ticker":"CAPR","relationship":"target"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"},{"name":"Reuters","relationship":"news source"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-27T19:33:27.738Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":128206,"modelName":"glm-4.7"}}